



Amyloid fibril polymorphism: Structural mechanisms of assembly and the links to disease

Alexander I. P. Taylor and Sheena E. Radford

Amyloid fibrils are involved in devastating conditions such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and systemic amyloidosis. They exhibit polymorphism, meaning that a single protein sequence can adopt different amyloid folds that vary with time and self-assembly conditions. Polymorphism confounds structure-based drug design and raises fundamental questions regarding why particular fibril structures form and how they cause disease. Here, we highlight the latest advances in our understanding of amyloid polymorphism, including its structural basis, thermodynamic origins, kinetic influences, and significance for disease. The next frontier will be to predict fibril structures, disentangle the dynamic mechanisms that guide the progression of fibril polymorphs, and illuminate how cofactors and the physiological milieu select for particular polymorphs in disease.

Addresses

Astbury Centre for Structural Molecular Biology, School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, LS2 9JT, UK

Corresponding author: Radford, Sheena E. (s.e.radford@leeds.ac.uk)

Current Opinion in Structural Biology 2026, 98:103245

This review comes from a themed issue on **Macromolecular Assemblies (2026)**

Edited by **Peter Rosenthal** and **Dina Schneidman**

For a complete overview see the [Issue](#) and the [Editorial](#)

Available online xxx

<https://doi.org/10.1016/j.sbi.2026.103245>

0959-440X/© 2026 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

Introduction

Amyloid fibrils are ordered protein assemblies that are involved in widespread diseases, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, type-2 diabetes, prion diseases, and systemic amyloidoses [1]. They are formed by over 40 different disease-related proteins [2] and have diverse structures, but all share a common architecture termed the cross- β amyloid fold [1,3,4]. Treatments targeting amyloid fibril formation have shown promise for tackling these devastating

conditions [5], but are hindered by amyloid polymorphism: the capacity for a single protein sequence to form amyloid fibrils with many different structures [3,6]. Polymorphism presents a challenge for structure-based drug design and raises fundamental questions regarding how amyloid fibril structures form and the relationship between structure and disease presentation.


Recently, cryogenic electron microscopy (cryo-EM) has fueled an explosion in the number of amyloid structures solved to near-atomic resolution [1,3,7], making it now possible to analyze large datasets of fibril structures to make sense of this diversity and uncover its underlying thermodynamic origins [8–11]. In addition, recent mechanistic studies have shed light on how proteins navigate the complex energy landscapes underpinning fibril polymorphism [12,13], and how changes in conditions or interactions with other molecules can steer polymorphism down a different path [13,14]. As a result, it is now possible to identify disease-related amyloid structural motifs that are promising therapeutic targets [7,15], and we are beginning to understand the processes that give rise to different fibril structures and how this relates to disease presentation [7,12,13,16].

Here we summarize the current understanding of amyloid polymorphism, including how polymorphs are generated and selected for *in vivo* and *in vitro*. We also discuss the mechanisms by which physiological conditions or cofactors funnel or steer polymorphism toward different fibril species, and how we can exploit this knowledge for future therapeutic interventions.

The amyloid fold

Amyloid fibrils are characterized by their cross- β structure, named after their signature X-ray diffraction pattern with orthogonal reflections at 4.7–4.8 Å and 8–11 Å [17,18]. Structurally, this results from the presence of continuous intermolecular β -sheets that run along the fibril axis, with a single amyloid fibril typically consisting of thousands of stacked subunit layers that collectively form these β -sheets (Figure 1a) [1,3]. The length of amyloid fibrils can vary enormously, from hundreds of nanometers to tens of micrometers, corresponding to hundreds to many thousands of subunits [1,3]. However, simulations suggest that short fragments may be stable down to stacks of just five subunits

Figure 1



Key characteristics of the amyloid fold. (a) Amyloid deposits consist of amyloid fibrils, each of which in turn consists of smaller filamentous units called protofilaments. Each protofilament is a stack of typically thousands of monomeric subunits, as illustrated here with a six-layer segment of an α -synuclein (α Syn) fibril structure (PDB ID: 6a6b [63]). Monomeric subunits usually have a flattened structure and each β -strand is part of a different intermolecular β -sheet. (b) Hydrophobic amino acids are usually buried in the fibril core, whereas polar amino acids are usually exposed. Key stabilizing interactions include steric zippers formed where side chains interlock to optimize hydrophobic contacts, and polar zippers formed by salt bridges or hydrogen bonding. (c) Different residues may make either a favorable or unfavorable contribution to the free energy of the fibril, and stabilizing residues are usually located in crucial zippers in the core. Plots in panels b and c were generated for the same fibril structure (PDB ID: 6a6b [63]) using the Amyloid Atlas Illustration Server [3].

[19], and diffusible fibril fragments are an increasingly recognized form of oligomer that has been detected in patient-derived samples [20]. Fibrils are hierarchically organized [16], with monomers stacking to form protofilaments that each contain one or more continuous intermolecular β -sheets, and which laterally associate with one another to form a complete fibril [1]. Typically, each constituent subunit has a flattened structure, optimizing its ability to hydrogen bond to the subunits above and below in the stack, and allowing each of its β -strands to be incorporated into a different ribbon-like intermolecular β -sheet (Figure 1a) [4]. However, some amyloid protofilaments, particularly those of functional amyloid, have layers that comprise different, complementary sequences [1,4]. The β -strands in a cross- β structure are usually oriented parallel and in-register with one another (Figure 1a) [1].

The extensive intermolecular β -sheets in amyloid fibrils entail the formation of massive, repetitive hydrogen bonding networks that run along the fibril axis [4]. As a result, hydrogen bonding has been suggested to make a greater contribution to the stability of amyloid fibrils than it does in globular proteins [21]. In agreement with this, density functional theory (DFT) calculations have

shown that interactions between repetitively stacked backbone or side chain hydrogen bonding moieties induce a cooperative polarization of their electron density [22]. This gives amyloid fibrils unusually strong hydrogen bonds, with more favorable formation energies than those seen between water molecules in ice [22]. At the same time, complementary interactions support β -sheet hydrogen bonding to further stabilize the fibril structure. These additional interactions are ubiquitous in amyloid fibril structures, and are believed to be key stabilizers of amyloid formation as well as determining specific amyloid folds [1,3,4]. Stacking of monomeric subunits is also supported by side chain–side chain interactions, particularly π -stacking and amide side chain hydrogen bonding, and disfavored by unfavorable electrostatics that result from alignment of like charges. Orthogonal to the fibril axis, subunit folding and association of protofilaments are driven by the hydrophobic effect and/or formation of salt bridges between oppositely charged residues (Figure 1b,c). Due to the repetitive structure of amyloid fibrils, these supporting interactions occur in zipper-like arrays, most commonly “steric zippers”, in which the side chains on adjacent stacks of polypeptide chains form corrugated, often tightly mated interfaces that optimize van der


Waals contacts, and “polar zippers”, in which adjacent stacks of polar moieties form salt bridges or hydrogen bonds with one another (Figure 1b) [3,4,23]. Due to the cooperativity between subunit stacking and folding, these complementary interactions all contribute to determining fibril structure. Non-protein cofactors may also be incorporated into the fibril structure and can play an important stabilizing role [6]. Lastly, the ordered cross- β core usually does not include the entire protein sequence, and many amyloid fibrils have a “fuzzy coat” consisting of disordered flanking regions than can span tens to hundreds of residues in length [24].

Amyloid polymorphism: one sequence, many structures

In contrast with globular protein folding, a single protein sequence can usually adopt many different structures in the amyloid state, a phenomenon termed polymorphism [6]. Polymorphism can involve differences at every level of a fibril's structural hierarchy (Figure 2a–c) [6]. Polymorphism exists for all types of amyloid fibrils, whether pathological, functional, or *in vitro* assembled.

For some disease-related proteins such as Tau or α -synuclein (α Syn), the amyloid fold observed across different individuals appears to be disease-specific [7,25], with different fibril structures associated with specific clinical presentations. However, this is not always the case as other disease-related proteins such as amyloid- β (A β) [26–28] and transthyretin [29,30] can form different fibril structures in the same disease, patient, or tissue. The diversity of antibody light chain (LC) sequences also means that different individuals with LC amyloidosis have different amyloid fibril structures, yet the same fibril structure has been found in different tissue deposits in a single individual [31,32]. Amyloid fibrils assembled from an individual protein sequence *in vitro* commonly result in an array of different structures under different but often closely related solution conditions (e.g. Refs. [7,12,14,33]), with multiple structures sometimes observed under the same conditions or even in a single self-assembly reaction [9]. This suggests that polypeptides have an intrinsic capacity to form different fibril structures, with specific features of the physiological environment selecting for a particular amyloid fold. Hence, cofactors such as metal ions, lipids,

Figure 2



Types of structural polymorphism. (a) Fibril structural polymorphism can involve differences in packing interactions (e.g. PHF and SF of Tau [37]), number (e.g. IAPP [14]), or structure (e.g. α Syn, classified in Ref. [9]) of the constituent protofilaments or a combination of all three of them. As shown in the center, different protofilament structures may also occur in the same fibril (L-fold vs U-fold of IAPP). (b) Protofilaments with different structures can have shared structural motifs, exemplified by a similar S-shaped fold of many A β (1–42) fibril polymorphs [26] and a shared U-shaped motif in some IAPP fibril polymorphs [14], highlighted in the overlays. (c) The ability to combine different protofilament structures or structural elements can result in hybrid fibrils. For example, α Syn fibrils in a patient with atypical multiple system atrophy (MSA) were found to contain a substructural motif similar to that seen in Lewy body disease (LBD) [34]. Furthermore, a single fibril may contain protofilaments from two proteins with completely different sequences, such as TDP-43 and ANXA11 in a patient with frontotemporal lobar degeneration (FTLD) [64]. In panels a and c, the schematics are simplified views of subunits looking down the fibril axis, with curved bars representing β -strands and connecting lines representing turns or loops. The coloring of chains distinguishes between adjacent monomer subunits, and the light gray background serves to enclose protofilaments that together make up the fibril. In the hybrid α Syn fibril in panel c, the purple chain segment marks a substructure within the MSA-like protofilament that resembles that found in LBD and the dark gray shape is non-proteinaceous density. IAPP, islet amyloid polypeptide; PHF, paired helical filament; SF, straight filament.

nucleic acids, or other ligands that associate with fibril structures (Figure 2c [34]), or the physicochemical environment of assembly (e.g. pH, cell type, subcellular location), can alter the structure that results. In turn, changes in fibril polymorphism may have important implications for disease. One possible explanation for disease-specific polymorphism is that different structures drive different pathologies. For example, α Syn fibril structures induced by binding heparin or covalent modification (e.g. phosphorylation or *O*-GlcNAcylation) have been shown to have reduced toxicity compared to fibrils formed under similar conditions without these cofactors or modifications [35,36].

Different interacting regions yield an alphabet of amyloid folds

Polymorphism can involve different packing arrangements of the same protofilament fold (e.g. paired helical filaments (PHFs) and straight filaments (SFs) of Tau [37]), different numbers of protofilaments with a similar fold (e.g. β_2 -microglobulin [38]), or protofilaments with the same sequence adopting different folds (e.g. α Syn [9]) (Figure 2a). In the case of islet amyloid polypeptide (IAPP), polymorphism involves different numbers and combinations of distinct protofilament folds, resulting in an alphabet-like classification of structures (Figure 2a) [12,14,39]. Protofilaments with different folds may share common structural units, such as identical β -arch motifs in the S-type and U-type protofilament folds of wild-type IAPP [14], or an S-shaped kernel at the core of many A β (1–42) protofilament structures that otherwise differ in conformation (Figure 2b) [26]. These shared motifs may point to a common mechanistic origin, or the involvement of the same stabilizing cofactors or physicochemical influences on the generation of each fibril type. How this occurs, however, remains unknown.

Now that >700 amyloid structures have been solved to near-atomic resolution [3], the structures of amyloid fibril polymorphs can be classified into distinct topological groups, reminiscent of CATH and SCOP for globular proteins [40,41]. The approaches used have involved hierarchical [8,9,11] or density-based [10] clustering performed on various measures of the similarity of protofilament structures. In one such study, Connor et al. [9] analyzed 169 high-resolution structures of α Syn and Tau fibrils to produce hierarchical trees of fibril folds for both proteins. Similar structural classes were identified for a smaller set of Tau fibrils by Mullapudi et al. [8] and α Syn fibril core segments by Milchberg et al. [10], despite each study using different methods. This demonstrates that fibril polymorphs can be organized into well-defined, meaningful fold families based on similarity at the sub-protofilament level. Intriguingly, polymorphs formed under different conditions or by different mutants can fall in the same fold family, while others form distinct structures in response

to seemingly minor changes in solution conditions. Hence, the determinants of polymorphism will be difficult to unpick. The existence of protofilament fold families also supports the notion that protofilament structures are built hierarchically by combining a restricted range of structural elements, whose capacity to form is apparently preprogrammed by sequence and solution conditions [12,42].


Defining the sequence regions that drive amyloid formation may hold the key to understanding how different protofilament folds are constructed. Although most polypeptide chains have an inherent capacity to form amyloid fibrils, some sequences are particularly amyloidogenic. Most proteins contain sequence regions that drive aggregation, termed aggregation-prone regions (APRs [43]), which have diverse sequences but the common properties of high β -sheet propensity, enrichment in aromatic, amide and hydrophobic sidechains, and high compatibility with steric zipper formation [44–46]. They are usually incorporated into the fibril core but a single APR may adopt diverse structures within the cores of different fibril polymorphs [12,13]. In parallel with this, Mullapudi et al. [8] and Connor et al. [9] demonstrated the existence of well-defined stabilizing regions in the sequences of Tau and α Syn, which typically make a favorable contribution to the free energy of the fibril across different polymorphs (Figure 3a). Some, but not all, of these overlap with known APRs. Interestingly, both studies observed distinct pairings (typically heterotypic steric zippers) between stabilizing regions in different fibril polymorphs. As a result, different fold families of Tau, α Syn, and likely other amyloid fibrils have characteristic, distinct patterns of interactions among the stabilizing regions within their cores (Figure 3b).

The inherent promiscuity of the interactions that support amyloid fibril structures presents a wide range of ways to build energetically similar fibril folds, leading to polymorphism (Figure 3c). This promiscuity may result from the unique organization of amyloid fibrils compared to globular proteins. Given the flattened structure of fibril subunits, which restrict folding to an approximately two-dimensional search for contacts, it is easy to see how relatively small deviations of the peptide backbone could allow a single stabilizing region to pair up with a wide range of other sequences (Figure 3b,c). In contrast, in the hydrophobic cores of globular proteins, where interactions must be optimized in three dimensions, such deviations may not be so easily tolerated.

Energy landscapes of amyloid polymorphs

Promiscuous interactions among stabilizing regions suggest how a single protein sequence can form many different amyloid polymorphs. For example, following the model of Connor et al. [9], where up to n stabilizing

Figure 3



Interacting sequence regions drive polymorphic amyloid formation. (a) Overlay of the per-residue free energy contributions of individual residues in 100 different α Syn fibril polymorphs (gray lines), adapted from Connor et al. [9], showing that the same 11 regions stabilize different amyloid folds. Note that different residues form the fibril core in different structures, with residues 1–100 incorporated into the core in at least one structure. The C-terminal residues 101–140 (not shown) are never incorporated into the core. Regions 5–9 are relevant to the next panel and have been colored. (b) Different α Syn fibril structures have distinct and characteristic patterns of interaction between stabilizing sequence regions, as demonstrated with α Syn classes 4 and 8 from Connor et al. [9]. The schematics are simplified views of subunits looking down the fibril axis, with curved bars representing β -strands and connecting lines representing turns, loops, or disordered regions. Particularly discriminatory sequence regions 5–9 have been colored using the same scheme as panel a, while the rest of the sequence is colored gray. The light gray background encloses protofilaments that together make up the fibril. Orange bands between sequence regions reflect close intra- and inter- protofilament interactions, typically steric zippers. Note that the large gap among protofilaments in class 4 is due to the presence of a stabilizing ionic polar zipper, rather than a close steric zipper interface. (c) Different patterns of interaction can be used to build fibril cores with different topologies but similar stability, resulting in polymorphism. The schematics shown are representative of four of the α Syn fibril classes (3, 4, 8, and 10, from left to right) identified in Connor et al. [9], and use the same coloring and representation of secondary structure as panel b. For clarity, we show only a single protofilament and focus on the part of the polypeptide chain containing sequence regions 5–9. However, fibrils in these classes often have more than one protofilament, which adds a further layer of complexity to the energy landscape of assembly. (d) In contrast to globular protein folding, the energy landscapes of amyloid fibrils can have many minima and energy barriers that impede conformational exploration [47,48]. However, cofactors or other aspects of the physiological milieu may stabilize particular polymorphs, reducing the number of minima and possibly having an effect similar to funneling. In this panel, the color scheme encodes different conformations rather than stabilizing sequence regions: black, monomer; green, an example globular fold; red, blue, and purple, various amyloid fibril polymorphs.

regions (dependent on sequence) may be incorporated into a given fibril fold and each region may interact with any other stabilizing region, the number of achievable fold topologies is $\sum_{k=1}^n \binom{n}{k} 2^{k(k-1)/2}$, where k is the number of regions incorporated and $\binom{n}{k}$ is a binomial coefficient reflecting the choice of which regions to incorporate. This is combinatorially explosive: while five interacting regions would permit 1449 topologies, 10 would permit approximately 3.6×10^{13} . Restricting the number of pairings allowed between regions—a plausible constraint to compare only isoenergetic

polymorphs—limits the number of options to $\sum_{k=1}^n \binom{n}{k} \binom{k(k-1)/2}{r}$, where r is the specified number of pairings. However, even here the numbers can still be enormous. Undoubtedly, steric constraints will limit these options, but other forms of polymorphism not accounted for by this model could also add to the diversity. The overall message is the same: the number of potentially energetically similar fibril polymorphs is huge. It is an amazing feat, therefore, that a single polymorph is commonly found in individuals associated with a particular disease (at least as visualized using high-resolution cryo-EM) [7].


The enormous number of possible structures and the large distance between their energy minima in conformational space suggests that the energy landscape of amyloid assembly is complex, highly rugged, and difficult to navigate [47,48] (Figure 3c–d). An analogy has been noted between the energy landscapes of amyloid polymorphism and those of glasses [48], whose multitude of comparable minima results in long-lasting, kinetically trapped out-of-equilibrium states, with extremely slow dynamics of maturation and relaxation to equilibrium. In the absence of evolved funneling or biasing cofactors, the same may be true for amyloid fibrils, explaining why *in vitro* self-assembly reactions are often so polymorphic (Figure 3d). On the other hand, the presence of dominant polymorphs in many diseases suggests that the physiological environment is sufficient either to funnel the energy landscape to a global minimum, or at least to create a deep enough local minimum that formation of other polymorphs is restricted (Figure 3d). As discussed later, it is also possible that disease structures may simply reflect out-of-equilibrium polymorphs that nucleate first and then self-propagate via secondary nucleation and elongation,

although this is neither proven nor guaranteed given the long timescales of *in vivo* assembly.

Amyloid polymorphism can change over time

The complexity of amyloid assembly energy landscapes means that it takes time for proteins to fully navigate them (Figure 3d), and polymorphism can depend on both the time of observation and the mechanism by which fibrils form (Figure 4). Early solid-state nuclear magnetic resonance (NMR) spectroscopy investigations showed that A β (1–40) forms a metastable amyloid polymorph under quiescent conditions *in vitro* that is replaced by a more stable polymorph later in the plateau phase [49]. More recently, other studies have demonstrated time-dependent changes in amyloid fibril polymorphism. For example, Pálmadóttir et al. [50] showed that α Syn can form two different fibril polymorphs under identical conditions *in vitro*, with distinct morphology, structural properties, and interactions, but the less stable polymorph was gradually replaced by the more stable one as time progressed. In addition, Farrell et al. [51] demonstrated the occurrence of two different IAPP fibril polymorphs during self-assembly,

Figure 4



Kinetic effects in amyloid fibril polymorphism. (a) Amyloid polymorphism changes over time, as shown *in vitro* at high resolution by Wilkinson et al. [12] for the disease-related S20G variant of human IAPP. (b) A hypothetical reaction scheme showing the mechanisms by which amyloid polymorphism may change over time, using IAPP S20G as an example [12]. (c) Interactions with ligands or surfaces during critical steps that determine the evolution of fibril polymorphism can change the structural outcome; illustrated with the example of wild-type IAPP, where compounds that interfere with primary nucleation led to new fibril structures [14]. In panels a and b, the schematics are simplified views of subunits looking down the fibril axis, with curved bars representing β -strands and connecting lines representing turns or loops. The coloring distinguishes chains with particular subunit folds, with a single color corresponding to a single or small number of related folds. The light gray background serves to enclose protofilaments that together make up the fibril. For panel c, the color scheme corresponds to the lineage of fibril structure: gray, undifferentiated monomer; blue, L-lineage; and red, C-lineage as well as a small molecule (YX-I-1) capable of kinetically steering fibrils toward that lineage. IAPP, islet amyloid polypeptide.

with an initial polymorph formed by primary nucleation and a later one by secondary nucleation.

High-resolution structural insights into the time-dependence of fibril polymorphism have been provided by two recent cryo-EM studies. Wilkinson et al. [12] used time-resolved cryo-EM to track the self-assembly of IAPP S20G, a disease-associated variant that is more aggregation-prone than wild-type IAPP and forms polymorphic fibrils (Figure 4a). Remarkably, cryo-EM revealed small amounts of fibrils in the lag phase, most of which are untwisted (and hence unsuitable for structure determination using helical reconstruction) but 32 % of which are twisted, enabling their two-protofilament P-fold to be determined. In the growth phase, twisted fibrils become more abundant and distinct L- and C-lineages of fibril folds emerge. The L- and C-lineages exhibit further polymorphism resulting from differences in the number of peripheral protofilaments, with the average number of protofilaments increasing over time as the plateau phase is reached (Figure 4a). In spite of these gross changes in fibril structure, the energetic refinements are modest, mainly resulting from the addition of inter-protofilament interactions in the large fibrils that dominate in the late stages of assembly. Similarly, Lövestam et al. [13] tracked the progression of Tau fibril polymorphism in buffers that ultimately lead to either the Alzheimer's disease (AD) or chronic traumatic encephalopathy (CTE) folds. They observed a similar increase in apparent twist and fold complexity over time, as well as a shared intermediate that occurred as the first cross- β containing structure under both conditions, and which they termed the first intermediate amyloid (FIA). Due to its order of occurrence, this was interpreted as the initial fibril polymorph formed by primary nucleation, prior to further structural maturation that leads to the AD and CTE folds.

While direct structural evidence for evolution of fibril structure *in vivo* has not yet been obtained, Fan et al. [52] recently demonstrated that α Syn fibrils seeded with cerebrospinal fluid from patients at different stages of Parkinson's disease have different structures and pathogenicity depending on the disease stage, with more advanced disease showing enhanced seeding activity and induction of pathology in primary neurons. This suggests that a similar slow maturation of fibril folds may occur *in vivo* and contribute to disease progression.

Polymorphism: kinetic or thermodynamic control?

The observation that amyloid polymorphism changes over time raises two key questions: how do new amyloid fibril polymorphs form during a self-assembly process, and how do kinetic and thermodynamic competition govern their changing abundance over time?

How polymorphs form and reorganize during assembly remains unclear. A variety of mechanisms must be involved, including primary nucleation, secondary nucleation on the surface of pre-existing fibrils, direct conformational conversion among early polymorphs that retain sufficient structural flexibility, and errors in templating during elongation (Figure 4b) [12,13,51,53]. Once formed, these polymorphs compete kinetically for monomers for growth and the fastest to self-replicate by elongation and secondary nucleation (or fragmentation) may then dominate [16]. In the plateau phase, when the monomer concentration approaches the solubility limit, kinetic competition is expected to give way to thermodynamic competition. Although very stable, amyloid fibrils exist in a slow dynamic equilibrium with monomers in solution [49,54,55] and undergo net disassembly if monomer levels decrease to below a certain critical concentration [54,55]. As monomer concentrations decline progressively throughout the plateau phase (at least *in vitro*), metastable polymorphs will begin to disassemble, starting with those that are least stable. As the least stable fibrils disassemble, the monomers released are repartitioned into more stable fibrils, until all monomers have been incorporated into the most stable fibril polymorph and a true monomer–fibril equilibrium can be reached [55]. However, we note that the situation *in vivo* could be very different, with continuous production of monomers by protein synthesis allowing more than one polymorph to remain stable indefinitely.

As well as thermodynamic stability, active processes may exert further selection pressures *in vivo*. Patient-derived amyloid fibrils formed by A β , serum amyloid A, antibody LC, and transthyretin exhibit enhanced protease resistance compared to fibrils formed *in vitro* by the same proteins, suggesting that only the most protease-resistant strains persist *in vivo* [56,57]. Differences in amyloid core structures and exposed fuzzy coats may also affect disaggregation by chaperones, as has been recently shown for different fibril polymorphs of α Syn [58]. Thus, the polymorphs that prevail in human disease may depend on a combination of strict thermodynamic stability and resistance to physiological quality control mechanisms. Nonetheless, an equivalent measure of effective stability is likely to govern competition between fibrils and drive changes in polymorphism.

Kinetics can also leave a lasting imprint on fibril polymorphism that persists deep into the plateau phase. Recently, we showed that two inhibitors (YX-1-1 and canagliflozin) profoundly affect the fibril polymorphs of IAPP formed at the end of fibril growth [14]. Neither compound achieves this simply by stabilizing an alternative fibril polymorph, but instead by interfering in early steps that determine fibril structure (Figure 4c). We thus propose the term *kinetic steering* to describe a

lasting change in fibril polymorphism that is wholly or partly kinetic in origin, rather than simply involving differential stabilization. Crucially, the fact that a change in polymorphism can last deep into the plateau phase suggests that the fibril structures that form without inhibitors are either not present or unable to thermodynamically out-compete the altered polymorphs. In support of this, we found that fibrils of wild-type IAPP with 2PF^S and L-family structures [14,39], which were dominant in the absence of an inhibitor, were undetectable in kinetically steered samples, suggesting that their formation is strongly suppressed [14]. Thus, kinetic modulators can exert a long-lasting effect on polymorphism by filtering the “palette” of polymorphs that initially forms, and on which thermodynamic selection can then operate. In principle, kinetic steering could also operate *in vivo*, and our results show that even weak, transient interactions between small molecules and proteins can lead to a sustained interaction as aggregation progresses, ultimately leading to a profound effect on fibril structure [14]. This suggests that interactions with drugs, metabolites, or other biomolecules present in the physiological milieu could profoundly affect the kinetic evolution and structure of amyloid fibrils observed.

Summary and outlook

The recent explosion of high-resolution amyloid structures, advances in computational approaches, and accumulation of mechanistic data have led to major advances in our understanding of fibril polymorphism. Despite this progress, fundamental questions remain.

Firstly, the rules that govern the pairing of sequence regions and selection of a particular amyloid fold are not understood. Addressing this gap will require new kinetic and structural analyses mapping how sequence regions pair to build fibril folds, as well as targeted experiments that seek to alter fold topology by mutagenesis, sequence modification, or addition of cofactors. Once a set of principles has been established, fibril structure prediction will provide a critical test of our understanding. State-of-the-art protein structure prediction tools such as AlphaFold [59] are currently unable to recapitulate observed fibril structures or their polymorphs, indicating that multiple sequence alignments are inappropriate for finding structures that have not been shaped by evolution, and the complexity of amyloid assembly energy landscapes will require different approaches to navigate computationally. Nonetheless, machine learning is promising for amyloid structure prediction [48], and models trained on deep mutational scanning datasets can already accurately predict sequence regions that stabilize the amyloid core [46] or facilitate conversion to the fibril state [60]. Despite this progress, fibril fold prediction remains in its infancy and accurate predictions of

polymorphism will likely require approaches that are able to navigate extensive conformational landscapes with many comparable minima. This will benefit from an improved understanding of how sequence regions pair to build fibril folds [9], as well as targeted strategies to account for kinetic considerations, physiological conditions, and cofactor binding.

There is also an urgent need to better understand the dynamic mechanisms that shape amyloid polymorphism *in vivo*, such as thermodynamic selection, kinetic effects and degradation by chaperones or proteases, and how these relate to cell-type vulnerability in different disease states. This will require high-resolution *ex vivo* structural data to be integrated with high-throughput techniques that are able to rapidly, accurately, and interpretably detect differences in polymorphism, and can be used in kinetic or mechanistic studies where the time taken for exhaustive structure determination would be prohibitive. Promising approaches include computational characterization of fibril morphology in EM or atomic force microscopy (AFM) images [33] and characterization using panels of polymorph-sensitive fluorescent dyes [61]. In addition, biophysical and computational analyses will be needed to elucidate the thermodynamic drivers and mechanistic basis of these processes, and *in situ* fibril structure determination will provide a powerful link between mechanisms and pathology [62]. A better understanding of the mechanisms that shape the evolution of amyloid fibril structure will be crucial to explain how toxicity occurs in these devastating protein folding diseases and to inspire the next generation of amyloid biomarkers and therapeutic strategies.

Funding sources

This work was funded by Wellcome (204963) (AIPT) and the Royal Society (RSRP\R1\211057) (SER).

Declaration of competing interest

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Sheena E Radford reports financial support was provided by The Royal Society. Alexander IP Taylor reports financial support was provided by Wellcome.

Acknowledgements

We thank members of the Radford, Brockwell, Calabrese, and Ranson laboratories, especially members of our amyloid team, for stimulating discussions and comments.

References

Papers of particular interest, published within the period of review, have been highlighted as:

- * of special interest
- ** of outstanding interest

1. Iadanza MG, Jackson MP, Hewitt EW, Ranson NA, Radford SE: **A new era for understanding amyloid structures and disease.** *Nat Rev Mol Cell Biol* 2018, **19**:755–773.
 2. Buxbaum JN, Eisenberg DS, Fändrich M, McPhail ED, Merlini G, Saraiva MJM, Sekijima Y, Westermark P: **Amyloid nomenclature 2024: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee.** *Amyloid* 2024, **31**:249–256.
 3. Sawaya MR, Hughes MP, Rodriguez JA, Riek R, Eisenberg DS: **The expanding amyloid family: structure, stability, function, and pathogenesis.** *Cell* 2021, **184**:4857–4873.
 4. Taylor AIP, Staniforth RA: **General principles underpinning amyloid structure.** *Front Neurosci* 2022, **16**, 878869.
 5. Stögmänn E, Schmidt R: **Amyloid-beta antibody treatment in Alzheimer's disease.** *Wien Klin Wochenschr* 2025, **137**: 182–188.
 6. Gallardo R, Ranson NA, Radford SE: **Amyloid structures: much more than just a cross- β fold.** *Curr Opin Struct Biol* 2020, **60**:7–16.
 7. Scheres SHW, Ryskeldi-Falcon B, Goedert M: **Molecular pathology of neurodegenerative diseases by cryo-EM of amyloids.** *Nature* 2023, **621**:701–710.
- An excellent review of recently solved high-resolution amyloid fibril structures from patient samples, showing the relationship between specific structures and pathology in neurodegeneration.
8. Mullanpudi V, Vaquer-Alicea J, Bommarreddy V, Vega AR, Ryder BD, White CL, Diamond MI, Joachimiak LA: **Network of hotspot interactions cluster tau amyloid folds.** *Nat Commun* 2023, **14**:895.
- Amyloid-forming sequence regions in the microtubule-associated protein Tau form networks of interactions that stabilize different amyloid fibril folds, resulting in discrete families with different fibril folds.
9. Connor JP, Radford SE, Brockwell DJ: **Structural and thermodynamic classification of amyloid polymorphs.** *Structure* 2025, **33**:1793–1804.e3.
- Large-scale hierarchical clustering of α Syn and Tau amyloid polymorphs showed that near-isoenergetic fibril fold families result from the promiscuous pairing of common stabilizing sequence regions.
10. Milchberg MH, Warmuth OA, Borcik CG, Dhavale DD, Wright ER, Kotzbauer PT, Rienstra CM: **Alpha-synuclein fibril structures cluster into distinct classes.** *Biophys J* 2025, **124**:2571–2582.
 11. Duran-Romana R, Schymkowitz J, Rousseau F, Louros N: **Energetic profiling reveals thermodynamic principles underlying amyloid fibril maturation.** *Nat Commun* 2025, **16**, 10081.
 12. Wilkinson M, Xu Y, Thacker D, Taylor AIP, Fisher DG, Gallardo RU, Radford SE, Ranson NA: **Structural evolution of fibril polymorphs during amyloid assembly.** *Cell* 2023, **186**: 5798–5811.e26.
- Landmark study revealing how amyloid fibrils navigate complex energy landscapes during amyloid fibril assembly and maturation. Time-resolved cryo-EM showed that S20G and wild-type IAPP form distinct fibril polymorphs in the lag, growth and plateau phases of *in vitro* self-assembly, revealing subtle, progressive energetic refinements and suggesting possible mechanisms of maturation.
13. Lövestam S, Li D, Wagstaff JL, Kotecha A, Kimanius D, McLaughlin SH, Murzin AG, Freund SMV, Goedert M, Scheres SHW: **Disease-specific tau filaments assemble via polymorphic intermediates.** *Nature* 2024, **625**:119–125.
- The authors combined time-resolved cryo-EM and polymorph-specific self-assembly conditions to structurally map how Tau fibrils with the AD and CTE folds form. Both initially nucleate as a common ancestor fibril, termed the first intermediate amyloid (FIA), which then undergoes further structural refinement guided by solvent conditions to adopt the mature AD and CTE folds.
14. Taylor AIP, Xu Y, Wilkinson M, Chakraborty P, Brinkworth A, Willis LF, Zhuravleva A, Ranson NA, Foster R, Radford SE: **Kinetic steering of amyloid formation and polymorphism by canagliflozin, a type-2 diabetes drug.** *J Am Chem Soc* 2025, **147**:11859–11878.
- Drug-like small molecules (canagliflozin, YX-I-1) that interfere in the early steps of IAPP amyloid formation are shown to kinetically steer the structural evolution of IAPP amyloid fibrils, profoundly affecting the fibril structures formed in the plateau-phase observed using cryo-EM.
- The results have wide-ranging implications for both therapeutic development and our understanding of polymorphism (or lack of it) *in vivo*.
15. Abskharon R, Pan H, Sawaya MR, Seidler PM, Olivares EJ, Chen Y, Murray KA, Zhang J, Lantz C, Bentzel M, et al.: **Structure-based design of nanobodies that inhibit seeding of Alzheimer's patient-extracted tau fibrils.** *Proc Natl Acad Sci U S A* 2023, **120**, e2300258120.
- Structure-based design of bispecific nanobodies that cap and thus inhibit seeding of Tau fibrils. The nanobodies have enhanced blood–brain barrier penetration compared to precursors.
16. Aubrey LD, Radford SE: **How is the amyloid fold built? Polymorphism and the microscopic mechanisms of fibril assembly.** *J Mol Biol* 2025, **437**, 169008.
- A comprehensive review of the molecular basis of amyloid fibril polymorphism and the kinetics of competition between polymorphs. Contains software enabling readers to simulate how structural diversity affects growth curves observed e.g. using thioflavin T.
17. Astbury WT, Dickinson S, Bailey K: **The X-ray interpretation of denaturation and the structure of the seed globulins.** *Biochem J* 1935, **29**:2351–2360.
 18. Eanes ED, Glenner GG: **X-ray diffraction studies on amyloid filaments.** *J Histochem Cytochem* 1968, **16**: 673–677.
 19. Zheng W, Tsai M-Y, Chen M, Wolynes PG: **Exploring the aggregation free energy landscape of the amyloid- β protein (1–40).** *Proc Natl Acad Sci U S A* 2016, **113**:11835–11840.
 20. Stern AM, Yang Y, Jin S, Yamashita K, Meunier AL, Liu W, Cai Y, Ericsson M, Liu L, Goedert M, Scheres SHW, Selkoe DJ: **Abundant A β fibrils in ultracentrifugal supernatants of aqueous extracts from Alzheimer's disease brains.** *Neuron* 2023, **111**:2012–2020.e4.
 21. Fitzpatrick AW, Knowles TPJ, Waudby CA, Vendruscolo M, Dobson CM: **Inversion of the balance between hydrophobic and hydrogen bonding interactions in protein folding and aggregation.** *PLoS Comput Biol* 2011, **7**, e1002169.
 22. Tsemekhman K, Goldschmidt L, Eisenberg D, Baker D: **Cooperative hydrogen bonding in amyloid formation.** *Protein Sci* 2007, **16**:761–764.
 23. Nelson R, Sawaya MR, Balbirnie M, Madsen AO, Riekel C, Grothe R, Eisenberg D: **Structure of the cross- β spine of amyloid-like fibrils.** *Nature* 2005, **435**:773–778.
 24. Ulamec SM, Brockwell DJ, Radford SE: **Looking beyond the core: the role of flanking regions in the aggregation of amyloidogenic peptides and proteins.** *Front Neurosci* 2020, **14**, 611285.
 25. Shi Y, Zhang W, Yang Y, Murzin AG, Falcon B, Kotecha A, van Beers M, Tarutani A, Kametani F, Garringer HJ, et al.: **Structure-based classification of tauopathies.** *Nature* 2021, **598**: 359–363.
 26. Yang Y, Arseni D, Zhang W, Huang M, Lövestam S, Schweighauser M, Kotecha A, Murzin AG, Peak-Chew SY, Macdonald J, et al.: **Cryo-EM structures of amyloid- β 42 filaments from human brains.** *Science* 2022, **375**:167–172.
 27. Fernandez A, Hoq MR, Hallinan GI, Li D, Bharath SR, Vago FS, Zhang X, Ozcan KA, Newell KL, Garringer HJ, et al.: **Cryo-EM structures of amyloid- β and tau filaments in Down syndrome.** *Nat Struct Mol Biol* 2024, **31**:903–909.
 28. Zhao Q, Tao Y, Yao Y, Liu K, Lv S, Cui B, Xiao W, Cao T, Li W, Gao F, et al.: **Unraveling Alzheimer's complexity with a distinct A β 42 fibril type and specific AV-45 binding.** *Nat Chem Biol* 2026, **22**:482–490.
 29. Iakovleva I, Hall M, Oelker M, Sandblad L, Anan I, Sauer-Eriksson AE: **Structural basis for transthyretin amyloid formation in vitreous body of the eye.** *Nat Commun* 2021, **12**: 7141.
 30. Nguyen BA, Singh V, Afrin S, Yakubovska A, Wang L, Ahmed Y, Pedretti R, Fernandez-Ramirez M del C, Singh P, Pekala M, et al.: **Structural polymorphism of amyloid fibrils in ATTR amyloidosis revealed by cryo-electron microscopy.** *Nat Commun* 2024, **15**:581.

31. Puri S, Schulte T, Chaves-Sanjuan A, Mazzini G, Caminito S, Pappone C, Anastasia L, Milani P, Merlini G, Bolognesi M, *et al.*: **The cryo-EM structure of renal amyloid fibril suggests structurally homogeneous multiorgan aggregation in AL amyloidosis.** *J Mol Biol* 2023, **435**, 168215.
 32. Karimi-Farsijani S, Pfeiffer PB, Banerjee S, Baur J, Kuhn L, Kupfer N, Hegenbart U, Schönland SO, Wiese S, Haupt C, *et al.*: **Light chain mutations contribute to defining the fibril morphology in systemic AL amyloidosis.** *Nat Commun* 2024, **15**:5121.
 33. Aubrey LD, Lutter L, Fennell K, Purton TJ, Ward NL, Serpell LC, *Xue W-F: **Structural reconstruction of individual filaments in A β 42 fibril populations assembled in vitro reveal rare species that resemble ex vivo amyloid polymorphs from human brains.** *Commun Chem* 2025, **8**:358.
- Atomic force microscopy (AFM) and image analysis allowed characterization of *in vitro* A β (1–42) fibril polymorphism in unprecedented detail, revealing a level of heterogeneity not accessible by ensemble techniques and illustrating the intrinsic capacity of amyloid fibrils for polymorphism.
34. Enomoto M, Martinez-Valbuena I, Forrest SL, Xu X, Munhoz RP, Li J, Rogaeva E, Lang AE, Kovacs GG: **Lewy-MSA hybrid fold drives distinct neuronal α -synuclein pathology.** *Commun Biol* 2025, **8**:929.
- A recent study showing a remarkable extension of the principle that specific amyloid fibril structures can correspond to particular disease phenotypes. Here, a patient with atypical Multiple System Atrophy (MSA) had fibrils with a hybrid fold containing features of fibrils found in both MSA and Lewy body disease (LBD).
35. Tao Y, Sun Y, Lv S, Xia W, Zhao K, Xu Q, Zhao Q, He L, Le W, Wang Y, *et al.*: **Heparin induces α -synuclein to form new fibril polymorphs with attenuated neuropathology.** *Nat Commun* 2022, **13**:4226.
 36. Hu J, Xia W, Zeng S, Lim Y-J, Tao Y, Sun Y, Zhao L, Wang H, Le W, Li D, *et al.*: **Phosphorylation and O-GlcNAcylation at the same α -synuclein site generate distinct fibril structures.** *Nat Commun* 2024, **15**:2677.
 37. Fitzpatrick AWP, Falcon B, He S, Murzin AG, Murshudov G, Garringer HJ, Crowther RA, Ghetti B, Goedert M, Scheres SHW: **Cryo-EM structures of tau filaments from Alzheimer's disease.** *Nature* 2017, **547**:185–190.
 38. Wilkinson M, Gallardo RU, Martinez RM, Guthertz N, So M, Aubrey LD, Radford SE, Ranson NA: **Disease-relevant β 2-microglobulin variants share a common amyloid fold.** *Nat Commun* 2023, **14**:1190.
 39. Gallardo R, Iadanza MG, Xu Y, Heath GR, Foster R, Radford SE, Ranson NA: **Fibril structures of diabetes-related amylin variants reveal a basis for surface-templated assembly.** *Nat Struct Mol Biol* 2020, **27**:1048–1056.
 40. Knudsen M, Wiuf C: **The CATH database.** *Hum Genom* 2010, **4**: 207.
 41. Andreeva A, Kulesha E, Gough J, Murzin AG: **The SCOP database in 2020: expanded classification of representative family and superfamily domains of known protein structures.** *Nucleic Acids Res* 2020, **48**:D376–D382.
 42. Louros N, Wilkinson M, Tsaka G, Ramakers M, Morelli C, Apostol M, Gallardo R, D'Haeyer S, Goossens V, Audenaert D, *et al.*: **Local structural preferences in shaping tau amyloid polymorphism.** *Nat Commun* 2024, **15**:1028.
- A new amyloidogenic motif, PAM4, was found to make a significant contribution to Tau fibril polymorphism. Moreover, the intrinsic structure propensity of amyloid-prone regions was shown to pre-program the polymorphism of fibril structures in disease.
43. Fernandez-Escamilla A-M, Rousseau F, Schymkowitz J, Serrano L: **Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins.** *Nat Biotechnol* 2004, **22**:1302–1306.
 44. Sawaya MR, Sambashivan S, Nelson R, Ivanova MI, Sievers SA, Apostol MI, Thompson MJ, Balbirnie M, Wiltzius JJW, McFarlane HT, *et al.*: **Atomic structures of amyloid cross- β spines reveal varied steric zippers.** *Nature* 2007, **447**: 453–457.
 45. Maurer-Stroh S, Debulpaep M, Kuemmerer N, de la Paz ML, Martins IC, Reumers J, Morris KL, Copland A, Serpell L, Serrano L, *et al.*: **Exploring the sequence determinants of amyloid structure using position-specific scoring matrices.** *Nat Methods* 2010, **7**:237–242.
 46. McKay CE, Deans M, Connor J, Saunders JC, Lloyd C, Radford SE, Brockwell DJ: **Employing deep mutational scanning in the *Escherichia coli* periplasm to decode the thermodynamic landscape for amyloid formation.** *Proc Natl Acad Sci U S A* 2025, **122**, e2516165122.
 47. Röder K, Wales DJ: **Energy landscapes for the aggregation of A β 17–42.** *J Am Chem Soc* 2018, **140**:4018–4027.
 48. Guo L, Yu Q, Wang D, Wu X, Wolynes PG, Chen M: **Generating the polymorph landscapes of amyloid fibrils using AI: Ribbonfold.** *Proc Natl Acad Sci U S A* 2025, **122**, e2501321122.
 49. Qiang W, Kelley K, Tycko R: **Polymorph-specific kinetics and thermodynamics of β -amyloid fibril growth.** *J Am Chem Soc* 2013, **135**:6860–6871.
 50. Pálmadóttir T, Waudby CA, Bernfur K, Christodoulou J, Linse S, Malmendal A: **Morphology-dependent interactions between α -synuclein monomers and fibrils.** *Int J Mol Sci* 2023, **24**:5191.
 51. Farrell KM, Fields CR, Dicke SS, Zanni MT: **Simultaneously measured kinetics of two amyloid polymorphs using cross peak specific 2D IR spectroscopy.** *J Phys Chem Lett* 2023, **14**: 11750–11757.
 52. Fan Y, Sun Y, Yu W, Tao Y, Xia W, Liu Y, Zhao Q, Tang Y, Sun Y, Liu F, *et al.*: **Conformational change of α -synuclein fibrils in cerebrospinal fluid from different clinical phases of Parkinson's disease.** *Structure* 2023, **31**:78–87.e5.
- Intriguing first indication that α Syn amyloid fibrils may have different structures in different stages of Parkinson's disease, analogous to *in vitro* observations for IAPP and Tau.
53. Radamaker L, Baur J, Huhn S, Haupt C, Hegenbart U, Schönland S, Bansal A, Schmidt M, Fändrich M: **Cryo-EM reveals structural breaks in a patient-derived amyloid fibril from systemic AL amyloidosis.** *Nat Commun* 2021, **12**:875.
 54. Buell AK: **Stability matters, too – the thermodynamics of amyloid fibril formation.** *Chem Sci* 2022, **13**:10177–10192.
 55. Pálmadóttir T, Getachew J, Ortigosa-Pascual L, Axell E, Wei J, Olsson U, Knowles TPJ, Linse S: **On the reversibility of amyloid fibril formation.** *Biophys Rev* 2025, **6**, 011303.
 56. Kollmer M, Close W, Funk L, Rasmussen J, Bsoul A, Schierhorn A, Schmidt M, Sigurdson CJ, Jucker M, Fändrich M: **Cryo-EM structure and polymorphism of A β amyloid fibrils purified from Alzheimer's brain tissue.** *Nat Commun* 2019, **10**:4760.
 57. Schönfelder J, Pfeiffer PB, Pradhan T, Bijzet J, Hazenberg BPC, Schönland SO, Hegenbart U, Reif B, Haupt C, Fändrich M: **Protease resistance of ex vivo amyloid fibrils implies the proteolytic selection of disease-associated fibril morphologies.** *Amyloid* 2021, **28**:243–251.
 58. Jäger S, Tittelmeier J, Dang TL, Bellande T, Redeker V, Buell AK, Hennig J, Melki R, Nussbaum-Krammer C, Bukau B, *et al.*: **Structural polymorphism of α -synuclein fibrils alters the pathway of Hsc70-mediated disaggregation.** *EMBO J* 2025, **44**:6499–6526.
- Six well-defined structural polymorphs of α Syn amyloid fibrils were found to exhibit differing sensitivity to the Hsc70-mediated disaggregate machinery, showing that chaperones may exert selection pressures on the survival and self-replication of amyloid fibril strains *in vivo*.
59. Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, Tunyasuvunakool K, Bates R, Zidek A, Potapenko A, *et al.*: **Highly accurate protein structure prediction with AlphaFold.** *Nature* 2021, **596**:583–589.
 60. Arutyunyan A, Seuma M, Faure AJ, Bolognesi B, Lehner B: **Massively parallel genetic perturbation suggests the energetic structure of an amyloid- β transition state.** *Sci Adv* 2025, **11**, eadv1422.
 61. Carroll EC, Yang H, Powell WC, Charvat AF, Oehler A, Jones JG, Montgomery KM, Yung A, Millbern Z, Taylor AIP, *et al.*: **High-throughput discovery of fluorophores that recognize amyloid fibril polymorphs.** *Nat Chem* 2025, **17**:1565–1575.

Recent study using protein-adaptive differential scanning fluorimetry (paDSF) as a high-throughput approach to screen for pan-fibril and polymorph-selective fluorophores for Tau, α Syn and IAPP amyloid fibrils, with potential for use in *in vitro* and *ex vivo* studies.

62. Gilbert MAG, Fatima N, Jenkins J, O'Sullivan TJ, Schertel A, Halfon Y, Wilkinson M, Morrema THJ, Geibel M, Read RJ, *et al.*: **CryoET of β -amyloid and tau within postmortem Alzheimer's disease brain.** *Nature* 2024, **631**:913–919.

Cryo-ET and a suite of accompanying techniques were used to characterize the *in situ* architecture of A β , Tau, and non-amyloid constituents in postmortem AD brains. Remarkably, subtomogram averaging yielded *in situ* Tau fibril structures to sub-nm resolution, and the orientation and interactions of A β and Tau fibrils provided tantalizing clues as to their formation mechanisms. This study paves the way for future *in situ* structural biology studies to link amyloid self-assembly mechanisms to pathology.

63. Li Y, Zhao C, Luo F, Liu Z, Gui X, Luo Z, Zhang X, Li D, Liu C, Li X: **Amyloid fibril structure of α -synuclein determined by cryo-electron microscopy.** *Cell Res* 2018, **28**:897–903.

64. Arseni D, Nonaka T, Jacobsen MH, Murzin AG, Cracco L, Peak-Chew SY, Garringer HJ, Kawakami I, Suzuki H, Onaya M, *et al.*: **Heteromeric amyloid filaments of ANXA11 and TDP-43 in FTLD-TDP type C.** *Nature* 2024, **634**:662–668.

A cryo-EM study showing, for the first time, that a single amyloid fibril core from human patient samples can contain protofilaments composed of proteins with unrelated sequences. This overturns pre-existing assumptions about amyloid fibril structure, and has important implications as we seek to understand how amyloid-forming proteins interact with each other in disease.